Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
33%
Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 31 (33.3%)
N/A2 (66.7%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completednot_applicable

Cost-utility Study of a Group of Compensatory Cognitive Remediation in Schizophrenia

NCT02879604
completednot_applicable

Adjustment With Aphasia After Stroke: SUPERB

NCT02947776
completedphase_3

Multi-National Phase III Vitala™ 12-Hour Wear Test

NCT00902252

Clinical Trials (3)

Showing 3 of 3 trials
NCT02879604Not Applicable

Cost-utility Study of a Group of Compensatory Cognitive Remediation in Schizophrenia

Completed
NCT02947776Not Applicable

Adjustment With Aphasia After Stroke: SUPERB

Completed
NCT00902252Phase 3

Multi-National Phase III Vitala™ 12-Hour Wear Test

Completed

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3